I-131 Tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: Radiation dose to the testes

被引：0
|
作者：
Hattori, Naoya [1 ]
Gopal, Ajay [1 ]
Fisher, Darrell [2 ]
Durack, Lawrence [1 ]
Shields, Andrew [1 ]
Press, Oliver [1 ]
Rajendran, Joseph [1 ]
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Pacific Northwest Natl Lab, Richland, WA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2009年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1836
引用
收藏
页数：2
相关论文
共 50 条
  • [1] 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes
    Hattori, Naoya
    Gopal, Ajay K.
    Shields, Andrew T.
    Fisher, Darrell R.
    Gooley, Ted
    Pagel, John M.
    Press, Oliver W.
    Rajendran, Joseph G.
    NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (12) : 1225 - 1231
  • [2] Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab
    Kaminski, MS
    Radford, JA
    Gregory, SA
    Leonard, JP
    Knox, SJ
    Kroll, S
    Wahl, RL
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) : 7985 - 7993
  • [3] Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma
    Dosik, AD
    Coleman, M
    Kostakoglu, L
    Furman, RR
    Fiore, JM
    Muss, D
    Niesvizky, R
    Shore, T
    Schuster, MW
    Stewart, P
    Vallabhajosula, S
    Goldsmith, SJ
    Leonard, JP
    CANCER, 2006, 106 (03) : 616 - 622
  • [4] Tositumomab and 131I therapy in non-Hodgkin's lymphoma
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2005, 46 : 128S - 140S
  • [5] Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma
    Burdick, Michael J.
    Macklis, Roger M.
    ONCOTARGETS AND THERAPY, 2009, 2 : 229 - 242
  • [6] Comparison of radiation dose estimation for myeloablative radioimmunotherapy for relapsed or recurrent mantle cell lymphoma using 13I tositumomab to that of other types of non-Hodgkin's lymphoma
    Rajendran, J
    Gopal, A
    Durack, L
    Fisher, D
    Press, O
    Eary, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (06) : 738 - 745
  • [7] Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma
    Illidge, Tim
    Ivanov, Andrei
    Du, Yong
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 621 - 631
  • [8] Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma:: Comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose
    Rajendran, Joseph G.
    Gopal, Ajay K.
    Fisher, Darrel R.
    Durack, Larry D.
    Gooley, Ted A.
    Press, Oliver W.
    JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (05) : 837 - 844
  • [9] Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement
    Mones, Jodi V.
    Coleman, Morton
    Kostakoglu, Lale
    Furman, Richard R.
    Chadburn, Amy
    Shore, Tsiporah B.
    Muss, Daniel
    Stewart, Patricia
    Kroll, Stewart
    Vallabhajosula, Shankar
    Goldsmith, Stanley J.
    Leonard, John P.
    LEUKEMIA & LYMPHOMA, 2007, 48 (02) : 342 - 348
  • [10] High-dose 131I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma:: Adjusting radiation absorbed dose to actual organ volumes
    Rajendran, JG
    Fisher, DR
    Gopal, AK
    Durack, LD
    Press, OW
    Eary, JF
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (06) : 1059 - 1064
12345